Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 19;22(1):148.
doi: 10.1186/s12958-024-01317-4.

Association of insulin resistance surrogate indices and erectile dysfunction: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Association of insulin resistance surrogate indices and erectile dysfunction: a systematic review and meta-analysis

Sayeh Jalali et al. Reprod Biol Endocrinol. .

Abstract

Background: Erectile dysfunction (ED) has been linked to insulin resistance (IR), with various surrogate indices being used to assess this association. This systematic review and meta-analysis aimed to evaluate the relationship between IR indices and the incidence and severity of ED.

Methods: A comprehensive search across PubMed, Embase, Web of Science, and Scopus was carried out. Required data were extracted and meta-analyzed. The Newcastle-Ottawa Scale (NOS) was employed to evaluate the studies' risk of bias. Sensitivity analyses and meta-regressions were conducted to explore heterogeneity and the impact of confounding variables.

Results: Seventeen studies with a total of 3810 patients with ED and 8252 without ED were included. Meta-analysis revealed that males with ED had significantly higher levels of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (SMD = 0.59, 95% CI [0.15, 1.03], I2 = 82%, P < 0.01), Triglyceride-Glucose Index (TyG) (SMD = 0.53, 95% CI [0.31, 0.75], I2 = 69%, P < 0.01), and Visceral Adiposity Index (VAI) (SMD = 0.45, 95% CI [0.25, 0.64], I2 = 76%, P < 0.01) compared to those without ED. However, there was no significant correlation between a one-unit increase in HOMA-IR (OR = 0.63, 95% CI [0.03, 13.69], I2 = 91%, P = 0.77) or TyG (OR = 0.53, 95% CI [0.02, 11.53], I2 = 88%, P = 0.68) and the odds of ED. Additionally, a one-unit increase in VAI was associated with more severe ED (SMD = 0.34, 95% CI [0.03, 0.64], I2 = 16%, P = 0.03). The diagnostic accuracy of these indices varied.

Conclusions: The results indicate a significant connection between insulin resistance and erectile dysfunction, as shown by HOMA-IR, TyG, and VAI. Yet, their usefulness in predicting ED is restricted because of significant differences and inconsistencies in diagnostic precision. More research is required to determine the clinical importance of these indices in treating ED.

Keywords: Erectile dysfunction; HOMA-IR; Insulin resistance; Male sexual health; Meta-analysis; Metabolic syndrome; Surrogate indices; Systematic review; Triglyceride-glucose index.

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flowchart
Fig. 2
Fig. 2
A Forest plot of the HOMA-IR index levels in ED vs. no ED patients; (B) Subgroup analysis based on NOS of the HOMA-IR index levels in ED vs. no ED patients
Fig. 3
Fig. 3
Sensitivity analysis of the HOMA-IR index levels in ED vs. no ED patients
Fig. 4
Fig. 4
A Forest plot of ED incidence using the HOMA-IR index as a continuous variable (1-unit increase); (B) Sensitivity analysis of ED incidence using the HOMA-IR index as a continuous variable (1-unit increase)
Fig. 5
Fig. 5
A Forest plot of the TyG index levels in ED vs. no ED patients; (B) Forest plot of ED incidence using the TyG index as a continuous variable (1-unit increase)
Fig. 6
Fig. 6
Forest plot of the VAI index levels in ED vs. no ED patients

References

    1. McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019;210:469–76. - PubMed
    1. Defeudis G, Mazzilli R, Tenuta M, Rossini G, Zamponi V, Olana S, Faggiano A, Pozzilli P, Isidori AM, Gianfrilli D. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022;38:e3494. - PMC - PubMed
    1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–6. - PubMed
    1. Lowy M, Ramanathan V. Erectile dysfunction: causes, assessment and management options. Aust Prescr. 2022;45:159–61. - PMC - PubMed
    1. Xu W, Jiang H, Liu J, Li H. Non-coding RNAs: New Dawn for diabetes mellitus induced erectile dysfunction. Front Mol Biosci. 2022;9:888624. - PMC - PubMed

LinkOut - more resources